Gastrointestinal and colorectal cancer
Research activity includes metastatic colorectal cancer, BRAF V600E-mutant mCRC, microsatellite stable and microsatellite instable colorectal disease, as well as gastric cancer and gastroesophageal junction cancer.
- BRAF-targeted treatment strategies
- Rechallenge approaches in metastatic disease
- Neoadjuvant treatment for gastric and GEJ cancer
- Colorectal and endometrial tumors with mismatch repair features
The portfolio also covers antibody-based and immune-based combinations in advanced digestive tract malignancies.
Breast, endometrial, and ovarian cancer
Clinical research spans HER2-positive breast cancer, refractory metastatic breast cancer, advanced or recurrent endometrial cancer, and high-grade serous or endometrioid ovarian, fallopian tube, and peritoneal cancer.
- HER2-directed therapy in advanced disease
- Platinum-pretreated endometrial cancer
- HRD-related ovarian and peritoneal tumors
- Gynae-oncology biomarker characterization
Interest also extends to homologous recombination deficiency assessment and biomarker-linked treatment selection in gynecologic malignancies.
Rare solid tumors and bone cancer
Studies include adrenocortical carcinoma, advanced high-grade osteosarcoma, localized renal cell carcinoma, and selected other advanced solid tumors.
- Adrenocortical carcinoma management
- High-grade osteosarcoma
- Renal cell carcinoma
- Basket-style evaluation across solid tumors
These programs address difficult-to-treat cancers with limited established therapeutic options.
Immunotherapy and cell therapy
Research includes immune checkpoint blockade-resistant solid tumors, melanoma, non-small cell lung cancer, cervical cancer, and advanced tumors treated with tumor-infiltrating lymphocyte therapy, natural killer cell therapy, and CAR-T cells.
- Checkpoint inhibitor combinations
- TIL-based adoptive cell therapy
- NK-cell and lymphocyte-based approaches
- Advanced immunologic tumor profiling
The portfolio also includes graft-versus-host disease and post-transplant immune research.
Molecular profiling and precision oncology
Work in this area focuses on HRD status, mismatch repair proficiency, MSI and MSS tumors, and matched therapy selection across molecularly defined cancer groups.
- Biomarker concordance testing
- Matched therapy in molecular subsets
- Personalized medicine in solid tumors
- Single-cell tumor characterization
These studies support treatment stratification in advanced cancers with distinct molecular signatures.
